BILL ANALYSIS
S3799
NEUTRALHealthy Start Reauthorization Act of 2026
S3799 (Healthy Start Reauthorization Act of 2026) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
neutral
Market Sentiment
0
Affected Stocks
1
Sectors Impacted
Key Takeaways for Investors
The bill authorizes $145M/year for the Healthy Start Initiative, a maternal health grant program.
It is an authorization, not an appropriation; actual funding requires a separate spending bill.
No publicly traded healthcare companies are directly impacted by this legislation.
How S3799 Affects the Market
No market implications. The bill is a routine reauthorization of a federal grant program that does not create new procurement, tax credits, or regulatory changes for any public company.
Bill Details
| Metric | Value |
|---|---|
| Bill Number | S3799 |
| Market Sentiment | neutral |
| Event Date | |
| Affected Sectors | Healthcare |
| Affected Stocks | N/A |
| Source | View on Congress.gov → |
Summary
The Healthy Start Reauthorization Act of 2026 (S. 3799) was reported favorably out of the Senate HELP Committee on June 17, 2026, and awaits floor action. It authorizes $145 million annually for FY2026-2030 for the Healthy Start Initiative, a maternal and child health grant program. This is an authorization, not an appropriation, and the direct financial impact on publicly traded healthcare companies is negligible.